NZ598891A - Synthesis of a neurostimulative piperazine - Google Patents

Synthesis of a neurostimulative piperazine

Info

Publication number
NZ598891A
NZ598891A NZ598891A NZ59889110A NZ598891A NZ 598891 A NZ598891 A NZ 598891A NZ 598891 A NZ598891 A NZ 598891A NZ 59889110 A NZ59889110 A NZ 59889110A NZ 598891 A NZ598891 A NZ 598891A
Authority
NZ
New Zealand
Prior art keywords
piperazine
synthesis
disubstituted
neurostimulative
nicotinic acid
Prior art date
Application number
NZ598891A
Other languages
English (en)
Inventor
Sripathy Venkatraman
Syed Mahmood
Bingidimi I Mobele
Olga Lapina
Kellie Vercoe
Ying Li
Jonathan Salsbury
Mark Mclaws
Original Assignee
Neuralstem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43649584&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ598891(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuralstem Inc filed Critical Neuralstem Inc
Publication of NZ598891A publication Critical patent/NZ598891A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ598891A 2009-08-24 2010-08-24 Synthesis of a neurostimulative piperazine NZ598891A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23647709P 2009-08-24 2009-08-24
PCT/US2010/046537 WO2011028548A1 (en) 2009-08-24 2010-08-24 Synthesis of a neurostimulative piperazine

Publications (1)

Publication Number Publication Date
NZ598891A true NZ598891A (en) 2014-05-30

Family

ID=43649584

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ598891A NZ598891A (en) 2009-08-24 2010-08-24 Synthesis of a neurostimulative piperazine

Country Status (22)

Country Link
US (2) US9278933B2 (oth)
EP (1) EP2470182B1 (oth)
JP (1) JP5727482B2 (oth)
KR (1) KR101701362B1 (oth)
CN (2) CN102711764A (oth)
AU (1) AU2010289802C1 (oth)
BR (1) BR112012004161B1 (oth)
CA (1) CA2772080C (oth)
CL (1) CL2012000493A1 (oth)
DK (1) DK2470182T3 (oth)
ES (1) ES2475721T3 (oth)
HR (1) HRP20140621T1 (oth)
IL (1) IL218298A (oth)
IN (1) IN2012DN02370A (oth)
MX (1) MX2012002335A (oth)
NZ (1) NZ598891A (oth)
PL (1) PL2470182T3 (oth)
PT (1) PT2470182E (oth)
RU (1) RU2567390C2 (oth)
SG (1) SG178867A1 (oth)
SI (1) SI2470182T1 (oth)
WO (1) WO2011028548A1 (oth)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012DN02370A (oth) * 2009-08-24 2015-08-21 Neuralstem Inc
JP7204640B2 (ja) * 2016-09-12 2023-01-16 ニューラルステム・インコーポレーテッド 糖尿病に関連する神経障害の改善
WO2018075667A1 (en) * 2016-10-18 2018-04-26 Neuralstem, Inc. Amelioration of radiation-induced cognitive dysfunction
US10042957B2 (en) 2017-01-12 2018-08-07 Innovationdock, Inc. Devices and methods for implementing dynamic collaborative workflow systems
US10413534B2 (en) * 2017-02-13 2019-09-17 Neuralstem, Inc. Amelioration of certain deficiencies due to stroke
CN117377664A (zh) * 2020-12-23 2024-01-09 贝勒医学院 孤儿核受体tlx的小分子调节剂
EP4346823A2 (en) 2021-06-03 2024-04-10 Alto Neuroscience, Inc. Method of treatment of depressed patients with poor cognition and selection of other patients benefiting from a benzylpiperazine-aminopyridine agent
US20240197721A1 (en) 2022-12-05 2024-06-20 Alto Neuroscience, Inc. Effective treatment of depression in patients having impaired learning and/or memory or certain eeg characteristics with a benzylpiperazine-aminopyridine agent
US12208096B2 (en) 2022-12-05 2025-01-28 Alto Neuroscience, Inc. Effective treatment of depression in patients having impaired learning and/or memory or certain EEG characteristics with a benzylpiperazine-aminopyridine agent
US12233059B2 (en) 2022-12-05 2025-02-25 Alto Neuroscience, Inc. Effective treatment of depression in patients having impaired learning and/or memory or certain EEG characteristics with a benzylpiperazine-aminopyridine agent

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU175075B (hu) * 1977-06-30 1980-05-28 Egyt Gyogyszervegyeszeti Gyar Sposob poluchenija piperazidov piridin-karbonovoj kisloty
JPS54122283A (en) * 1978-03-13 1979-09-21 Sumitomo Chem Co Ltd Novel quinazoline derivative and its preparation
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
ES2335488T3 (es) 2002-03-29 2010-03-29 Schering Corporation Alquilacion estereoselectiva de piperazinas quirales 2-metil-4-protegidas.
GB0222493D0 (en) * 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
WO2004053071A2 (en) * 2002-12-09 2004-06-24 Judith Kelleher-Andersson Method for discovering neurogenic agents
PT1663232E (pt) * 2003-09-09 2007-12-12 Hoffmann La Roche Derivados de 1- (2-amino-benzol) -piperazina como inibidores de absorção de glicina para o tratamento de psicoses
BRPI0518068A (pt) * 2004-10-29 2008-10-28 Banyu Pharma Co Ltd composto ou um éster ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, inibidor seletivo de aurora a, agente anti-tumor, e, preparação combinada
US7754724B2 (en) * 2005-06-30 2010-07-13 Dow Agrosciences Llc N-substituted piperazines
RU2008129622A (ru) 2005-12-20 2010-01-27 Новартис АГ (CH) Производные никотиновой кислоты в качестве модуляторов метаботропных глутаматных рецепторов
IN2012DN02370A (oth) * 2009-08-24 2015-08-21 Neuralstem Inc

Also Published As

Publication number Publication date
BR112012004161A2 (pt) 2016-03-29
RU2012111227A (ru) 2013-10-10
CL2012000493A1 (es) 2012-09-28
SI2470182T1 (sl) 2014-10-30
WO2011028548A1 (en) 2011-03-10
AU2010289802B2 (en) 2014-10-02
CA2772080C (en) 2017-05-30
EP2470182B1 (en) 2014-06-04
ES2475721T3 (es) 2014-07-11
HRP20140621T1 (hr) 2014-11-21
MX2012002335A (es) 2012-07-04
CN102711764A (zh) 2012-10-03
JP5727482B2 (ja) 2015-06-03
KR20120054642A (ko) 2012-05-30
RU2567390C2 (ru) 2015-11-10
US20130005974A1 (en) 2013-01-03
JP2013502462A (ja) 2013-01-24
AU2010289802C1 (en) 2015-04-16
DK2470182T3 (da) 2014-07-21
AU2010289802A1 (en) 2012-04-12
HK1172844A1 (en) 2013-05-03
IL218298A0 (en) 2012-04-30
US9278933B2 (en) 2016-03-08
CA2772080A1 (en) 2011-03-10
US9481649B2 (en) 2016-11-01
KR101701362B1 (ko) 2017-02-01
EP2470182A4 (en) 2013-04-24
IN2012DN02370A (oth) 2015-08-21
BR112012004161B1 (pt) 2020-04-07
SG178867A1 (en) 2012-04-27
US20160090358A1 (en) 2016-03-31
CN105693601A (zh) 2016-06-22
PL2470182T3 (pl) 2015-05-29
EP2470182A1 (en) 2012-07-04
PT2470182E (pt) 2014-07-24
IL218298A (en) 2017-03-30

Similar Documents

Publication Publication Date Title
NZ598891A (en) Synthesis of a neurostimulative piperazine
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
GEP20115343B (en) New method for preparing functionalised benzocyclo-butenes and its application to the synthesis of ivabradine and its addition salts with a pharmaceutically acceptable acid
IN2012DN03182A (oth)
MX367154B (es) Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benz oico.
MY148258A (en) Phenylamino-benzoxazole substituted carboxylic acids, method for their production and use thereof as medicaments
MY149648A (en) Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
MX2009014104A (es) Metodos para sintetizar cinacalcet y sales del mismo.
GEP20125491B (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
MX2010008051A (es) Nuevos derivados de fluoroglicosidos aromaticos, productos farmaceuticos que comprenden dichos compuestos y uso de los mismos.
MX2012013274A (es) Novedosos derivados de la pirimidina.
MX2009007436A (es) Derivados espirociclicos de acido tetronico.
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MY156630A (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
MY150014A (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
IL200323A0 (en) Synthesis of glyt-1 inhibitors
MX2010009876A (es) Nuevo proceso para la preparacion de derivados de acido ciclohexanocarboxilico por medio del derivado de ciclohexanocarboxamida correspondiente.
MX2010001512A (es) Nuevo procedimiento de preparacion.
GEP20125460B (en) New process for the synthesis of ivabradine and its pharmaceutically acceptable acid addition salts
MX2010004505A (es) Piperidinas 4,4-disustituidas.
TW200738704A (en) New process for the production of tiotropium salts
MX2013004193A (es) Procedimiento para la preparacion de derivados de acido 3-(6-amino-piridin-3-il)-2-acrilico.
UA106208C2 (ru) Способ синтеза ивабрадина и его аддитивных солей с фармацевтически приемлемой кислотой
GEP20156269B (en) New secondary 8-hydroxyquinoline-7- carboxamide derivatives
NZ599218A (en) Process for the manufacture of organic compounds

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 24 AUG 2017 BY GRIFFITH HACK

Effective date: 20141218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 AUG 2018 BY CPA GLOBAL

Effective date: 20170713

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 AUG 2019 BY CPA GLOBAL

Effective date: 20180712

LAPS Patent lapsed